Renaissance Technologies (RenTech)'s IMNM Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 68,902 shares of Immunome, Inc. (IMNM) worth $1.51 M, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in IMNM, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 304,700 shares. Largest reduction occurred in Q4 2025, reducing 202,300 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Immunome (IMNM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Immunome (IMNM) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +68,902 | New Buy | 68,902 | $21.87 |
| Q4 2025 | -202,300 | Sold Out | 0 | $0.00 |
| Q3 2025 | +102,928 | Add 103.58% | 202,300 | $11.71 |
| Q2 2025 | -16,628 | Reduce 14.33% | 99,372 | $9.30 |
| Q1 2025 | -200,000 | Reduce 63.29% | 116,000 | $6.73 |
| Q4 2024 | +304,700 | Add 2696.46% | 316,000 | $10.62 |
| Q3 2024 | -82,000 | Reduce 87.89% | 11,300 | $14.62 |
| Q2 2024 | +47,782 | Add 104.97% | 93,300 | $12.10 |
| Q1 2024 | -75,982 | Reduce 62.54% | 45,518 | $24.67 |
| Q4 2023 | +89,100 | Add 275.00% | 121,500 | $10.70 |
| Q3 2023 | -12,100 | Reduce 27.19% | 32,400 | $8.36 |
| Q2 2023 | +15,600 | Add 53.98% | 44,500 | $0.01 |
| Q1 2023 | +7,800 | Add 36.97% | 28,900 | $0.00 |
| Q4 2022 | -400 | Reduce 1.86% | 21,100 | $0.00 |
| Q2 2022 | +7,500 | Add 53.57% | 21,500 | $3.21 |
| Q1 2022 | +14,000 | New Buy | 14,000 | $5.71 |
| Q3 2021 | -20,400 | Sold Out | 0 | $0.00 |
| Q2 2021 | +20,400 | New Buy | 20,400 | $17.30 |
Renaissance Technologies (RenTech)'s Immunome Investment FAQs
Renaissance Technologies (RenTech) first purchased Immunome, Inc. (IMNM) in Q2 2021, acquiring 20,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Immunome, Inc. (IMNM) for 19 quarters since Q2 2021.
Renaissance Technologies (RenTech)'s largest addition to Immunome, Inc. (IMNM) was in Q4 2024, adding 316,000 shares worth $3.36 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 68,902 shares of Immunome, Inc. (IMNM), valued at approximately $1.51 M.
As of the Q1 2026 filing, Immunome, Inc. (IMNM) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Immunome, Inc. (IMNM) was 316,000 shares, as reported at the end of Q4 2024.